Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Forward Pharma KRASG12C compound 20
- Development stage
- Unknown
- Lead developer
- Forward Pharma
01
Overview
Forward Pharma KRASG12C compound 20: sourced facts only. name: "This design strategy yielded compounds 19 and 20, which displayed sub-nanomolar cellular potency against KRASG12C-driven cell proliferation (NCI-H358, IC50 = 0.5 nM for both) and crucially retained potent activity against the clinically relevant KRAS G12C-R68S resistance variant (Ba/F3, IC50 = 29.8 nM and 5.4 nM, respectively)." [PMID:41187566]; target: "This design strategy yielded compounds 19 and 20, which displayed sub-nanomolar cellular potency against KRASG12C-driven cell proliferation (NCI-H358, IC50 = 0.5 nM for both) and crucially retained potent activity against the clinically relevant KRAS G12C-R68S resistance variant (Ba/F3, IC50 = 29.8 nM and 5.4 nM, respectively)." [PMID:41187566]; developer: "Forward Pharmaceuticals Co. Ltd., Shenzhen, 518063, Guangdong Province, PR China." [PMID:41187566]
02
Targets
Beyond the preview
Go deeper on Forward Pharma KRASG12C compound 20.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Forward Pharma KRASG12C compound 20.